Subscribe to our Newsletters !!


    New therapeutic system for tumors like Non-Hodgkin lymphoma: Immunotherapy

    Today, immunotherapy is one of the most encouraging treatment for malignant growth patients. In contrast to radio-or chemo-treatments, immunotherapy intends to “switch on” the patient’s own resistant framework to assault and wipe out the tumor. In any case, tumors, including NHL, frequently change to make themselves undetectable to the invulnerable framework or even adventure cooperations

    MD Anderson and Sanofi work together to quicken improvement of imaginative malignant growth treatments

    At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer. “Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via

    Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

    In this new role, Stewart will work as part of the Executive staff to drive Adaptate’s Business and Corporate Development activities. Stewart Kay, CBO, Adaptate Biotherapeutics Adaptate is developing a range of therapeutic antibodies that recognize drug targets and have the potential to modulate the activity of gamma delta T cells. Gamma delta T cells

    Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients

    Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the

    Novel hydrogel gradually delivers RNA nanovaccines to shrivel tumors

    Messenger RNA (mRNA) vaccines to stop COVID-19 have made headlines around the world recently, but scientists also have been working on mRNA vaccines to treat or prevent other diseases, including some forms of cancer. Cancer immunotherapy vaccines operate similarly to mRNA vaccines for COVID-19, except they trigger the immune system to attack tumors rather than

    Bacteria residing within inside tumor cells can support malignant growth immunotherapy

    Cancer immunotherapy may get a boost from an unexpected direction: bacteria residing within tumor cells. The study may also help clarify the connection between immunotherapy and the intestine microbiome, describing the findings of earlier research that the microbiome impacts the success of immunotherapy. Immunotherapy remedies of the last decade or so have dramatically improved healing

    UCL researchers distinguish new immunotherapy to battle hepatitis B infection

    Researchers at UCL have identified a new immunotherapy to fight the hepatitis B virus (HBV), the most frequent cause of liver cancer in the world. The pioneering study used immune cells isolated directly from patient liver and tumour tissue, to demonstrate that targeting acyl-CoA:cholesterol acyltransferase (ACAT), an enzyme which helps to manage cholesterol levels in

    Researchers develop experimental direct-acting antiviral treatment to treat COVID-19

    An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19. Conventional antivirals reduce symptoms and help people recover earlier. Examples

    Weight-based dosing procedure may influence immunotherapy results, shows study

    Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT Southwestern Medical Center. The findings, published in the Journal for ImmunoTherapy of Cancer, run counter to current practice trends, which favor fixed dosing, in which